Celltific Scientific Limited 14868155 false 2024-06-01 2025-05-31 2025-05-31 The principal activity of the company is that of importing and selling of instruments for laboratory use. Digita Accounts Production Advanced 6.30.9574.0 true true 14868155 2024-06-01 2025-05-31 14868155 2025-05-31 14868155 bus:OrdinaryShareClass1 2025-05-31 14868155 core:CurrentFinancialInstruments 2025-05-31 14868155 core:CurrentFinancialInstruments core:WithinOneYear 2025-05-31 14868155 bus:SmallEntities 2024-06-01 2025-05-31 14868155 bus:AuditExemptWithAccountantsReport 2024-06-01 2025-05-31 14868155 bus:FilletedAccounts 2024-06-01 2025-05-31 14868155 bus:SmallCompaniesRegimeForAccounts 2024-06-01 2025-05-31 14868155 bus:RegisteredOffice 2024-06-01 2025-05-31 14868155 bus:Director1 2024-06-01 2025-05-31 14868155 bus:OrdinaryShareClass1 2024-06-01 2025-05-31 14868155 bus:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 14868155 bus:Agent1 2024-06-01 2025-05-31 14868155 countries:EnglandWales 2024-06-01 2025-05-31 14868155 2023-05-15 2024-05-31 14868155 2024-05-31 14868155 bus:OrdinaryShareClass1 2024-05-31 14868155 core:CurrentFinancialInstruments 2024-05-31 14868155 core:CurrentFinancialInstruments core:WithinOneYear 2024-05-31 14868155 core:CurrentFinancialInstruments core:WithinOneYear core:PreviouslyStatedAmount 2024-05-31 14868155 core:PreviouslyStatedAmount 2024-05-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 14868155 (England and Wales)

Celltific Scientific Limited
Unaudited Filleted Financial Statements
for the Year Ended 31 May 2025

Celltific Scientific Limited

Contents

Company Information | 1
Balance Sheet | 2
Notes to the Unaudited Financial Statements | 3 to 6

Celltific Scientific Limited

Company Information

Director | Mr Shailendra Rambaran Singh

Registered office | 10 Colwick Quays Business Park Road No.2 Colwick Nottingham NG4 2JY

Accountants | Aventus Partners Limited Chartered AccountantsHygeia Building Ground Floor 66-68 College Road Harrow Middlesex HA1 1BE

Celltific Scientific Limited

(Registration number: 14868155) (England and Wales)
Balance Sheet as at 31 May 2025

| Note | 2025 £ | 2024 £
Current assets |  |  |
Stocks | 4 | 40,550 | -
Debtors | 5 | 9,303 | 100
Cash at bank and in hand |  | 2,377 | -
|  | 52,230 | 100
Creditors: Amounts falling due within one year | 6 | (56,109) | -
Net (liabilities)/assets |  | (3,879) | 100
Capital and reserves |  |  |
Called up share capital | 7 | 100 | 100
Retained earnings |  | (3,979) | -
Shareholders' (deficit)/funds |  | (3,879) | 100

For the financial year ending 31 May 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

• | The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476; and
• | The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

The financial statements were approved and authorised for issue by the director on 9 January 2026

......................................... Mr Shailendra Rambaran Singh Director |  |

Celltific Scientific Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 May 2025

1 | General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
10 Colwick Quays Business Park
Road No.2
Colwick
Nottingham
NG4 2JY
England

These financial statements were authorised for issue by the director on 9 January 2026.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The functional and presentational currency is GBP Sterling (£), being the currency of the primary economic environment in which the company operates in. The amounts are presented rounded to the nearest pound.

Going concern

At the time of approving these financial statements, the directors are confident that the company has adequate resources to continue in operational existence for the foreseeable future and are willing to provide the necessary financial support as necessary and accordingly these financial statements have been prepared on a going concern basis.

Celltific Scientific Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 May 2025 (continued)

2 | Accounting policies (continued)

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Celltific Scientific Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 May 2025 (continued)

2 | Accounting policies (continued)

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Financial instruments

Classification
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties and loans from related parties.
Recognition and measurement
Debt instruments (other than those wholly repayable or receivable within one year), including loans and other debtors and creditors, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method.
Debt instruments that are payable or receivable within one year, typically trade creditors or debtors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration, expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms of financed at a rate of interest that is not a market rate or in case of an out-right short term loan not at a market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.
Impairment
Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss if recognised in the Profit and loss account.
For financial assets measured as amortised cost, the impairment loss is measured as the difference between an asset’s carrying amount and the present value of estimated cash flows discounted at the asset’s original effective interest rate. If a financial asset has a variable interest rate, the discounted rate for measuring any impairment loss is the current effective interest rate determined under the contract.
Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

3 | Staff numbers

The average monthly number of persons employed by the company (including the director) during the year, was 1 (2024: 1).

Celltific Scientific Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 May 2025 (continued)

4 | Stocks

| 2025 £ | 2024 £
Other inventories | 40,550 | -

5 | Debtors

| 2025 £ | 2024 £
Other debtors | 8,734 | 100
Prepayments | 569 | -
| 9,303 | 100

6 | Creditors

Creditors: amounts falling due within one year

| Note | 2025 £ | 2024 £
Due within one year |  |  |
Trade creditors |  | 34,669 | -
Amounts owed to group undertakings and undertakings in which the company has a participating interest |  | 14,770 | -
Accruals and deferred income |  | 1,300 | -
Directors current account |  | 5,370 | -
|  | 56,109 | -

7 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Ordinary shares of £1 each | 100 | 100 | 100 | 100